Author

Dirk Jan A. R. Moes

Observed names: D J A Moes, D J A R Moes, D. J. A. R Moes, D. J. A. R. Moes, D. Moes, D.-J. Moes, D.J. Moes, D.J.A. Moes, D.J.A.R. Moes, Dirk J A R Moes, Dirk J. A. R. Moes, Dirk J.A.R. Moes, Dirk Jan A R Moes, Dirk Jan A.R. Moes, Dirk Jan AR Moes, Dirk Jan Alie Roelof Moes, Dirk Jan Moes, Dirk Jan. A. R. Moes, Dirk jan Moes, Dirk-Jan A. R. Moes, Dirk-Jan A.R. Moes, DirkJan A. R. Moes, Moes, Dirk J., Moes, Dirk Jan A.R.

Institutions: Leiden University, Leiden University Medical Center

Observed institutions: Leiden University, Radboud University Nijmegen, University of Groningen, Leiden University Medical Center, Catharina Ziekenhuis, Radboud University Medical Center, Maastricht University, Isala, KU Leuven

ORCID: 0000-0003-3219-253X

Observed ORCID: 0000-0003-3219-253X

OpenAlex ID: A5058166328

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

2019 · Mercè Brunet, Teun van Gelder, et al. · Therapeutic Drug Monitoring · 707

Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug–Drug Interactions

2020 · Laure Elens, Loralie J. Langman, et al. · Therapeutic Drug Monitoring · 677

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

2019 · Maddalena Centanni, Dirk Jan A. R. Moes, et al. · Clinical Pharmacokinetics · 356

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

2021 · Stein Bergan, Mercè Brunet, et al. · Therapeutic Drug Monitoring · 209

A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors

2019 · Anyue Yin, Dirk Jan A.R. Moes, et al. · CPT Pharmacometrics & Systems Pharmacology · 194

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

2019 · Kioa Lente Wijnsma, Rob ter Heine, et al. · Clinical Pharmacokinetics · 135

Sirolimus and everolimus in kidney transplantation

2015 · Dirk Jan A.R. Moes, Henk-Jan Guchelaar, et al. · Drug Discovery Today · 125

Medication non-adherence after kidney transplantation: A critical appraisal and systematic review

2019 · Sumit R.M. Gokoel, Kim B. Gombert-Handoko, et al. · Transplantation Reviews · 115

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen

2019 · A.B. Sanchez-Spitman, J.J. Swen, et al. · Expert Review of Clinical Pharmacology · 107

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients

2018 · L. M. Andrews, D. A. Hesselink, et al. · British Journal of Clinical Pharmacology · 104

Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device

2018 · Tom C. Zwart, Sumit R.M. Gokoel, et al. · British Journal of Clinical Pharmacology · 99

Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study

2019 · Anabel Sanchez-Spitman, Vincent Dezentjé, et al. · Journal of Clinical Oncology · 94

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

2022 · S.L. Groenland, R.A.G. van Eerden, et al. · Annals of Oncology · 83

Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients

2012 · Dirk Jan A.R. Moes, Rogier R. Press, et al. · Clinical Pharmacokinetics · 80

The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients

2020 · Teun van Gelder, Soufian Meziyerh, et al. · Frontiers in Pharmacology · 71

Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics

2020 · Soufian Meziyerh, Tom C. Zwart, et al. · American Journal of Transplantation · 63

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients

2015 · D. J. A. R Moes, S. A. S van der Bent, et al. · European Journal of Clinical Pharmacology · 61

Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19

2022 · Florian Lemaitre, Klemens Budde, et al. · Therapeutic Drug Monitoring · 56

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

2016 · D. de Wit, T. C. Schneider, et al. · Cancer Chemotherapy and Pharmacology · 53

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

2017 · A. B. Sanchez Spitman, D. J. A. R. Moes, et al. · European Journal of Clinical Pharmacology · 52

Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients

2022 · Tom C. Zwart, Erik Metscher, et al. · British Journal of Clinical Pharmacology · 50

Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group–Therapeutic Drug Monitoring Protocol for a Prospective Study

2019 · Stefanie L. Groenland, Ruben A. G. van Eerden, et al. · Therapeutic Drug Monitoring · 50

Development and Bioequivalence of 3D ‐Printed Medication at the Point‐of‐Care: Bridging the Gap Toward Personalized Medicine

2023 · Maryam Lyousoufi, Iris Lafeber, et al. · Clinical Pharmacology & Therapeutics · 49

High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT : a prospective multicentre study

2017 · M. Y. Eileen C. van der Stoep, Alice Bertaina, et al. · British Journal of Haematology · 45

Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology

2021 · Etienne Chatelut, Jeroen J. M. A. Hendrikx, et al. · Pharmacology Research & Perspectives · 41

Works count: 173

Citation count: 4,842

H-index: 32

I10-index: 74